Skip to main navigation
Skip to search
Skip to main content
The Hebrew University of Jerusalem Home
Approve / Request updates on publications
Link opens in a new tab
Search content at The Hebrew University of Jerusalem
Home
Profiles
Research units
Research output
Prizes
TorS - Reframing a rational for type 2 diabetes treatment
Jacob Bar-Tana
*
*
Corresponding author for this work
Braun School of Public Health and Community Medicine
Research output
:
Contribution to journal
›
Review article
›
peer-review
1
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'TorS - Reframing a rational for type 2 diabetes treatment'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Mammalian Target of Rapamycin (mTOR)
100%
Type 2 Diabetes Prevention
100%
Neurodegeneration
50%
Psoriasis
50%
Disease Entity
50%
Standard of Care
50%
Polycystic Ovary Syndrome
50%
Type 2 Diabetes Mellitus (T2DM)
50%
Type 2 Diabetic Patients
50%
Hypertension
50%
Obesity Type
50%
Novel Treatments
50%
Non-alcoholic Fatty Liver Disease (NAFLD)
50%
Type 2 Diabetic
50%
Diabetic Nephropathy
50%
Diabetic Hyperglycemia
50%
Diabetic Dyslipidemia
50%
Diabetic Cardiomyopathy
50%
Diabetic Peripheral Neuropathy
50%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
100%
Diseases
75%
Glycemic
50%
Cancer
25%
Diabetes Mellitus
25%
Neurodegeneration
25%
Dyslipidemia
25%
Hyperglycemia
25%
Mammalian Target of Rapamycin Complex 1
25%
Nonalcoholic Fatty Liver
25%
Psoriasis
25%
Diabetic Nephropathy
25%
Polycystic Ovary Syndrome
25%
Diabetic Neuropathy
25%
Diabetic Cardiomyopathy
25%
Hypertension
25%
Arteriosclerotic Heart Disease
25%